Literature DB >> 3498752

Polyclonal activation of the murine immune system by an antibody to IgD. VIII. Stimulation of IgD secretion.

J D Mountz1, J Smith, C M Snapper, J F Mushinski, F D Finkelman.   

Abstract

The low levels of serum IgD found in mice and the lack of a typical DNA switch sequence between C delta and C mu raise the possibility that the generation of murine IgD-secreting cells results from a chance "mistake" rather than a controlled process. The recent observation that injection of mice with purified IgD upregulates IgD receptor expression on helper T cells and enhances the ability of these T cells to induce B cells to differentiate into antibody secreting cells led us to look for evidence of controlled differentiation of B cells into IgD-secreting cells. To do this, we injected mice with a goat antibody to IgD (GaM delta), because this antibody stimulates large increases in IgM, IgG1, IgG2a, and IgE secretion. Mice injected with GaM delta demonstrated a large increase in splenic content of mRNA specific for the secreted form of delta-chain, as well as a greater than 100-fold increase in the percentage of splenic IgD-containing plasmablasts. The secretory IgD response was totally T-dependent. Production of the secretory form of IgD was not seen until 7 days after GaM delta injection, and peaked sharply on day 8, whereas by day 6 IgM secretion had already peaked and IgG1 and IgG2 secretion had attained substantial levels. This observation suggests that: 1) either cells that synthesize large quantities of the secretory form of delta-chain, unlike cells that synthesize large quantities of the secretory forms of gamma-, epsilon-, or alpha-chains, do this without deleting C mu, or, despite the absence of a typical DNA switch sequence between C mu and C delta, controls must exist to effect the C mu deletion and VDJ-C delta joining; and 2) if secreted IgD has a role in the regulation of a humoral immune response it most likely is involved in later processes, such as memory cell generation or response termination, rather than in relatively early processes, such as helper T cell activation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498752

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking.

Authors:  Richard T Strait; Suzanne C Morris; Fred D Finkelman
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

2.  The Mertk receptor tyrosine kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking.

Authors:  Wen-Hai Shao; Yuxuan Zhen; Fred D Finkelman; Philip L Cohen
Journal:  J Autoimmun       Date:  2014-04-24       Impact factor: 7.094

3.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

4.  Nonhomologous recombination at sites within the mouse JH-C delta locus accompanies C mu deletion and switch to immunoglobulin D secretion.

Authors:  J D Owens; F D Finkelman; J D Mountz; J F Mushinski
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

5.  IgD antibodies to DNP are specifically induced in ascitic fluid after intraperitoneal immunization.

Authors:  M G Steele; G A Leslie
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

6.  Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice.

Authors:  F D Finkelman; A Svetic; I Gresser; C Snapper; J Holmes; P P Trotta; I M Katona; W C Gause
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.